Clinical trials: Group A Streptococcus
Group B Streptococcus, Invasive Bacterial Diseases (IBD)
Preparing for Maternal GBS Vaccine Trials in Africa
Infections are one of the key causes of newborn deaths. Among them, Group B Streptococcus (GBS) is the leading cause of sepsis and bacterial meningitis in the first 90 days of life.
- Conditions
- Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization
- Trial name
- PROTECT (NCT06833957)
- Where
- 10 sites in Kenya, Malawi and 2 more
- Volunteers
- 18,100 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Group B Streptococcus Infection
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and…
- Trial name
- NCT06280157
- Testing
- GBS-NN/NN2
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Group B Streptococcus Infections
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
Phase 1/2, randomized, placebo-controlled, observer-blinded study will evaluate the safety, tolerability and immunogenicity of the investigational multivalent group B streptococcus vaccine administered at one dose level (various…
- Trial name
- NCT03765073
- Testing
- Multivalent Group B streptococcus vaccine
- Where
- 35 sites in United States, South Africa and 1 more
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pfizer
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
Globally, neonatal mortality remains unacceptably high, with little change in the death rate in the first 28 days of life since 1990, despite reductions in under-5 mortality of up to 50% over the same period.
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- ProGreSs (NCT04549220)
- Where
- Uganda
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Group B Streptococcus Infection
Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine
This is an open label booster vaccine follow-up study. Participants who had received a primary course of GBS-NN/NN2 or placebo in Study MVX0002 will be invited to return to receive a booster dose (or first dose in the case of…
- Trial name
- NCT05005247
- Testing
- GBS-NN/NN2
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Group B Streptococcus Infections
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with…
- Trial name
- NCT04766086
- Testing
- Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine
- Where
- 12 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bacterial Infection Due to Streptococcus, Group B, Streptococcus Agalactiae
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
The objective of this extension study is the initial assessment of safety and immunogenicity of the second dose of GBS Trivalent Vaccine following the time interval that is close to the inter-pregnancy interval observed in the…
- Trial name
- NCT02690181
- Testing
- GBS Trivalent Vaccine
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Group B Streptococcus Carrier in Childbirth, Gastrointestinal Symptoms
The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.
This study is a randomized double blind, placebo controlled trial to determine the efficacy of an oral probiotic in reducing antenatal Group B Streptococcus colonization.
- Trial name
- NCT03696953
- Testing
- Florajen3
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Marquette University
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital
Maternal immunisation is an evolving field that deserves special attention given its potential to have a significant positive impact on the health of women and children globally, and the potential safety and risk considerations…
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- PREPARE (NCT04653948)
- Where
- Uganda
- Volunteers
- 3,423 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Group B Streptococcus Carrier in Childbirth
Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization
This is a double-blind randomized placebo controlled trial that will investigate whether the use of three specific species of probiotics taken orally in pregnancy from 25 weeks gestation will reduce the incidence of Group B…
- Trial name
- OPSiP (NCT03407157)
- Testing
- Probiotic supplementation
- Where
- 2 sites in Canada
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Streptococcus, Other Specified Group, Dental Plaque
Efficacy of the Extract of Carica Papaya as an Inhibitor of Streptococcus Mutans
Papaya has effects on oral pathogenic microorganisms, it also has anticoagulant quality, amebicidal action, antimicrobial, bacteriostatic and antifungal activity on different bacteria, especially on Streptococcus mutans, this can…
- Trial name
- NCT04485520
- Testing
- CARICA PAPAYA MOUTHWASH, CHLORHEXIDINE MOUTHWASH
- Where
- Paraguay
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Julieta María Méndez Romero
Orthodontic Appliance Complication, Lactobacillus Infection
SPACE MAINTAINERS EFFECTS ON ORAL MİCROFLORA
Space maintainers are used to preserve the space after premature loss of teeth but they could effect some factors that play a role in caries formation.
- Conditions
- Orthodontic Appliance Complication, Lactobacillus Infection, Dental Caries in Children, Streptococcus, Other Specified Group
- Trial name
- NCT04749654
- Testing
- The Salivary pH measured, The saliva flow rate was measured, Streptococcus mutans and Lactobacillus counts in saliva were measured
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Infection by Streptococcus Group B
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.
Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus. Part B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year following the…
- Trial name
- MVX13211 (NCT02459262)
- Testing
- GBS-NN vaccine
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
Group A Streptococcus (GAS) infection is a major cause of death and disability globally with a disproportionately high burden in settings of disadvantage worldwide.
- Conditions
- Streptococcus Pyogenes Pharyngitis, Streptococcus Pharyngitis, Strep Throat, Streptococcus Pyogenes Infection
- Trial name
- CHIVAS (NCT03361163)
- Testing
- emm75 Streptococcus pyogenes (GAS M75, strain 611024)
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Andrew Steer
Group B Streptococcus
Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
Group B Streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis. In 2015, it was estimated that worldwide there were at least 320,000 infants with invasive GBS disease, 90,000 infant deaths and 10,000 cases of…
- Trial name
- TIMING (NCT04059510)
- Testing
- rectovaginal swab, pregnancy test, Menstrual cup
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Group B Streptococcus (GBS) Disease
A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine
This study looks at the body's immune response to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P2 study. Blood will be drawn and evaluated for GBS antibody levels.
- Trial name
- NCT01053767
- Testing
- Group B streptococcus (GBS) vaccine
- Where
- Switzerland
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Streptococcus Group B
Development and Optimization of a GBS Diagnostic Test
The purpose of this clinical study is to develop an easily performed test to detect Group B Streptococcus (GBS) in pregnant women at the time of delivery, which would allow health care providers to make an accurate and rapid…
- Trial name
- NCT00322829
- Where
- Canada
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Laval University
Streptococcus Group A
Rheumatic Heart Disease Prevalence in Leon, Nicaragua
A bacterium called Group A Steptoccoccus or "strep" is commonly found in the nose and throat of healthy adults and children and can cause a variety of illnesses.
- Trial name
- NCT00307112
- Where
- Nicaragua
- Volunteers
- 2,193 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Group B Streptococcus Disease
GBS Sero-correlate of Protection
Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not.
- Trial name
- V98_28OBTP (NCT02215226)
- Where
- South Africa
- Volunteers
- 35,274 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Immunisation During Pregnancy, Group B Streptococcus
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
Group B Streptococcus (GBS) is the commonest cause of severe infection and meningitis in babies under 3 months in the United Kingdom (UK).
- Trial name
- NCT01982084
- Where
- 4 sites in United Kingdom
- Volunteers
- 758 people, healthy volunteers welcome
- Sponsor
- University of Oxford